more_reports

Solving a 10,000-Pound Problem: This Company Aims to Reinvent the Brain Scan

  ()
Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW2:XFRA) is preparing to open its first dedicated brain PET imaging clinic as new Alzheimer's treatments drive demand for earlier, specialized imaging.
Tags: Medical DevicesLife Sciences Tools & Diagnostics

Can AI Find the Right Cancer Drug for the Right Patient? This Collaboration Is Putting It to Work

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V; RKVTF:OTCPK; 7JO0:FSE) partners with Celvion on AI-driven precision strategies for its ATR inhibitor.
Tags: Biotechnology / Pharmaceuticals

Sernova and Seraxis Bet on BetaNova to Take Diabetes Cell Therapy Into the Clinic

  ()
Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) and Seraxis Holdings Inc. are moving toward a merger to form BetaNova Biotherapeutics, with a type 1 diabetes cell therapy trial planned for early 2027. Find out why one analyst says Sernova found the right partner.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / PharmaceuticalsMedical DevicesHealthcare Services

Nektar's Phase 2b Data Shows Durable Eczema, Alopecia Response

  ()
Nektar Therapeutics (NKTR:NASDAQ) reports durable Phase 2b responses for rezpegaldesleukin in eczema and alopecia areata, as the Treg-targeted drug advances toward Phase 3.
Tags: Biotechnology / Pharmaceuticals

Aldeyra Plans FDRR to Appeal FDA Reproxalap CRL for Dry Eye

  ()
Aldeyra Therapeutics Inc. (ALDX:NASDAQ) announces intent to submit Formal Dispute Resolution Request appealing March 2026 CRL for reproxalap in dry eye disease. Here is a plain-English guide to the FDA appeal process for investors.
Tags: Biotechnology / Pharmaceuticals

Satellos Targets Untapped FSHD Market With FDA-Cleared IND for Phase 2 Trial

  ()
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) received FDA clearance of its IND application for a planned Phase 2 study of forazapadin in FSHD; US$5M non-dilutive funding and quotes highlight regeneration potential where no therapies exist.
Tags: Biotechnology / Pharmaceuticals

Rocket Pharmaceuticals Advances Danon Disease Gene Therapy Trial With FDA Alignment

  ()
Rocket Pharmaceuticals Inc. (RCKT:NASDAQ) receives FDA alignment to continue its Phase 2 RP-A501 trial for Danon disease, with nine additional patients expected to be treated by mid-2027.
Tags: Biotechnology / Pharmaceuticals

Fennec Pharmaceuticals Reports PEDMARK Data Showing Reduced Hearing Loss in Japanese Study

  ()
Fennec Pharmaceuticals Inc. (FENC:NASDAQ;FRX:TSE) reports Phase 2 STS-J01 results for PEDMARK in Japan, with ASHA-defined hearing loss in 24% of patients versus a 56.4% benchmark.
Tags: Biotechnology / Pharmaceuticals

Coya Enrolls 100 Patients in Phase 2/3 ALS Trial of COYA 302

  ()
Coya Therapeutics reaches 100-patient enrollment in its Phase 2/3 ALSTARS trial for COYA 302 in ALS, with full enrollment and topline data expected soon. Learn key catalysts for investors.
Tags: Biotechnology / Pharmaceuticals

Medicus's Pfizer Deal Was Not a Fire Sale: A Strategic Bet on De-Risked ADC Drug

Contributed Opinion
  ()
Mike Sheikh shares his thoughts on Medicus Pharma Ltd. (MDCX:NASDAQ) after its recent deal with Pfizer Inc. (PFE:NYSE).
Tags: Biotechnology / Pharmaceuticals

Coya Therapeutics Advances COYA 302 ALS Trial With 100th Participant

  ()
Coya Therapeutics Inc. (COYA:NASDAQ) enrolls its 100th participant in the Phase 2/3 ALSTARS trial of COYA 302 for ALS, with topline data expected in early Q2 2027.
Tags: Biotechnology / Pharmaceuticals

Rocket Doctor AI Delivers 3625 U.S. Patient Visits in July and August

  ()
Rocket Doctor AI reports 3,625 completed U.S. patient visits in the first two months of Q3 2026. The update highlights ongoing U.S. expansion and telehealth momentum for retail investors.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

US Patient Visits Reach 93% of Prior Quarter's Total in Two Months

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported 3,625 completed U.S. patient visits in July and August, alongside 1,555 clinical hours as its U.S. operations expanded.
Tags: Healthcare ServicesLife Sciences Tools & Diagnostics

Chart Buy Signals After Co. Targeting U.S. Alzheimer's Market Reports Final Major Regulatory Milestone

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson reviews Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW0:FRA) following its achievement of a major regulatory milestone.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

BioLargo Subsidiary Secures Spartan Medical Deal for ViaCLYR Government Sales

  ()
BioLargo subsidiary Clyra enters an exclusive reseller agreement with Spartan Medical for ViaCLYR wound care solution targeting U.S. government facilities and ECAT listing amid expanding wound care demand.
Tags: TechnologyHealthcare ServicesCleantechSpecial Situations

Cleantech Firm Expands Breakthrough Wound Solution to Veterans

  ()
BioLargo Inc. (BLGO:OTCQX) is bringing its FDA-cleared ViaCLYR wound solution to U.S. government and VA-contracted healthcare facilities through a new deal with Spartan Medical.
Tags: TechnologyHealthcare ServicesCleantechSpecial Situations

Biotech and Life Sciences Stock News

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Sernova-Seraxis Merger to Create BetaNova with US$10M for T1D Islet Trial

  ()
Sernova and Seraxis have entered into a definitive agreement to merge and create BetaNova Biotherapeutics, with US$10 million in financing to advance stem cell-derived islet therapy for type 1 diabetes, targeting Phase 1/2 data by mid-2027.
Tags: Biotechnology / PharmaceuticalsMedical Devices

Biotechs Combine to Target Type 1 Diabetes Treatment

  ()
Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) has agreed to merge with privately held Seraxis to form BetaNova Biotherapeutics, a U.S.-based company advancing cell therapies for type 1 diabetes. Find out why one analyst calls the combination a good strategic move.
Tags: Biotechnology / PharmaceuticalsMedical Devices

Telehealth Platform Delivers 196% U.S. Visit Growth in Q2

  ()
Rocket Doctor AI reports 43% revenue growth and 196% U.S. patient visit increase in Q2 2026, backed by 24 million covered lives and an expanding payer network.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Digital Health Platform Sees US Patient Visits Surge 196% and Quarterly YoY Revenue Jumps 43%

  ()
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported Q2 revenue of US$734,028 as U.S. patient visits nearly tripled and its in-network coverage expanded to approximately 24 million lives.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Rakovina Therapeutics Shifts 72% of Budget to AI Cancer Programs

  ()
Rakovina Therapeutics allocated 72% of its budget to AI-powered drug discovery in the second quarter of 2026, up from 57% in Q2 2025. See the three AI-supported DDR programs and upcoming milestones for retail investors.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services